Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats

References

• Abraham S, Steen V. (2015). Optimal management of digital ulcers in systemic sclerosis. Ther Clin Risk Manag 11:939–47.
   PubMed Web of Science ®Google Scholar
• Barst RJ, Ivy D, Dingemanse J, et al. (2003). Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 73:372–82.
   PubMed Web of Science ®Google Scholar
• Brammer KW, Farrow PR, Faulkner JK. (1990). Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 12(Suppl 3): S318–S26.
   PubMedGoogle Scholar
• Canu B, Fioravanti A, Orlandi P, et al. (2011). Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia 13:217–29.
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. (2001). Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358:1119–23.
   PubMed Web of Science ®Google Scholar
• Chen M, Song W, Wang S, et al. (2016). Simultaneous determination of bosentan, glimepiride, HYBOS and M1 in rat plasma by UPLC-MS-MS and its application to pharmacokinetic study. J Chromatogr Sci 54:1159–65.
   PubMedGoogle Scholar
• Dingemanse J, van Giersbergen PL. (2004). Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 43:1089–115.
   PubMed Web of Science ®Google Scholar
• Fattinger K, Funk C, Pantze M, et al. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–31.
   PubMed Web of Science ®Google Scholar
• Funke C, Farr M, Werner B, et al. (2010). Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. J Gen Virol 91:1959–70.
   PubMed Web of Science ®Google Scholar
• Garzone PD, Kroboth PD. (1989). Parmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 6:337–64.
   Google Scholar
• George LT. (2007). The importance of plasma protein binding in drug discovery. Expert Opin Drug Discov 2:51–64.
   PubMed Web of Science ®Google Scholar
• Hamberg P, Woo MM, Chen LC, et al. (2011). Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemother Pharmacol 68:805–13.
   PubMed Web of Science ®Google Scholar
• Hulin A, Dailly E, Le Guellec C, Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique, et al. (2011). Level of evidence for therapeutic drug monitoring of voriconazole. Therapie 66:109–14.
   PubMed Web of Science ®Google Scholar
• Humbert M, Segal ES, Kiely DG, et al. (2007). Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 30:338–44.
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. (2003). Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540–7.
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Kunze KL, Allen KE, et al. (2004). Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121–31.
   PubMed Web of Science ®Google Scholar
• Kunze KL, Wienkers LC, Thummel KE, Trager WF. (1996). Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 24:414–21.
   PubMed Web of Science ®Google Scholar
• Lin G, Wang C, Qiu X, et al. (2014). Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Drug Dev Ind Pharm 40:1616–22.
   PubMed Web of Science ®Google Scholar
• Markova SM, De Marco T, Bendjilali N, et al. (2013). Association of CYP2C9*2 with bosentan-induced liver injury. Clin Pharmacol Ther 94:678–86.
   PubMed Web of Science ®Google Scholar
• Mikus G, Scholz IM, Weiss J. (2011). Pharmacogenomics of the triazole antifungal agent voriconazole. Pharmacogenomics 12:861–72.
   PubMed Web of Science ®Google Scholar
• Niwa T, Shiraga T, Takagi A. (2005). Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 28:1805–8.
   PubMed Web of Science ®Google Scholar
• Pea F, Furlanut M. (2001). Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 40:833–68.
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. (2002). Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346:896–903.
   PubMed Web of Science ®Google Scholar
• Sakaeda T, Iwaki K, Kakumoto M, et al. (2005). Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 57:759–64.
   PubMed Web of Science ®Google Scholar
• Siniscalchi A, Gallelli L, Avenoso T, et al. (2011). Effects of carbamazepine/oxycodone coadministration in the treatment of trigeminal neuralgia. Ann Pharmacother 45:e33.
   PubMedGoogle Scholar
• Sitbon O, Gressin V, Speich R, et al. (2004). Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170:1212–7.
   PubMed Web of Science ®Google Scholar
• Spriet I, Grootaert V, Meyfroidt G, et al. (2013). Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction. Eur J Clin Pharmacol 69:737–8.
   PubMed Web of Science ®Google Scholar
• Tsunoda SM, Velez RL, Von Moltke LL, et al. (1999). Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 66:461–71.
   PubMed Web of Science ®Google Scholar
• van Giersbergen PL, Halabi A, Dingemanse J. (2002). Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 53:589–95.
   PubMed Web of Science ®Google Scholar
• Venitz J, Zack J, Gillies H, et al. (2012). Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol 52:1784–805.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2000). Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111–80.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Schmider J, et al. (1996). Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36:783–91.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang S, Chen M, et al. (2015). Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats. Drug Dev Ind Pharm 41:1661–6.
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H, et al. (1999). Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 39:703–14.
   PubMed Web of Science ®Google Scholar
• Weber C, Gasser R, Hopfgartner G. (1999). Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 27:810–5.
   PubMed Web of Science ®Google Scholar
• Weber C, Schmitt R, Birnboeck H, et al. (1996). Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin Pharmacol Ther 60:124–37.
   PubMed Web of Science ®Google Scholar
• Zhang J, He K, Cai L, et al. (2016). Inhibition of bile salt transport by drugs associated with liver injury in primary hepatocytes from human, monkey, dog, rat, and mouse. Chem Biol Interact 255:45–54.
   PubMed Web of Science ®Google Scholar